AdvairFDA Panel: Serevent & Foradil aren’t worth risk but backs Advair
A FDA Panel said Thursday that the risks of death and serious injury associated with two popular brands of asthma inhalers are greater than the benefits of the drugs. However, in what is sure to be a controversial opinion, the panel said that Advair should continue to be used to treat asthma.
facebook
rss
twitter